|Bid||164.23 x 0|
|Ask||164.26 x 0|
|Day's range||163.16 - 167.00|
|52-week range||119.01 - 167.66|
|PE ratio (TTM)||46.17|
|Forward dividend & yield||2.01 (1.21%)|
|1y target est||N/A|
CAMBRIDGE, Mass.--(BUSINESSWIRE)-- Seqirus announced today that the U.S. Food and Drug Administration (FDA) has approved AFLURIA QUADRIVALENT (Influenza Vaccine) for use in people five years of age and ...
RIGA, Latvia--(BUSINESSWIRE)-- Annual influenza-related hospitalizations among U.S. children younger than the age of 5 have ranged from 7,000 to 26,000 since 2010, and annual reported influenza-related ...
SUMMIT, N.J.--(BUSINESSWIRE)-- Seqirus announced today it has begun shipping its portfolio of seasonal influenza vaccines to customers in the United States for the 2017-2018 influenza season. Seqirus, ...
HOLLY SPRINGS, N.C.--(BUSINESSWIRE)-- Seqirus, a leading innovator in influenza vaccines and pandemic preparedness, today announced the next major advancement in the use of cell-based technology at its ...